Q1 LAA < 7.5% | Q2 LAA 7.5–15% | Q3 LAA 15–25% | Q4 LAA 25% | p-value (ANOVA) | |
---|---|---|---|---|---|
Subjects (n) | 9 | 11 | 13 | 10 | |
Demographics | |||||
Age years | 64 ± 9 | 65 ± 8 | 67 ± 7 | 66 ± 8 | NS |
Male sex % | 68 | 70 | 78 | 76 | < 0.001 |
BMI (kg m−2) | 26 ± 7 | 27 ± 5 | 25 ± 6 | 23 ± 6 | < 0.001 |
BMI < 21 kg m−2% | 14 | 12 | 19 | 30 | < 0.001 |
Smoking status | |||||
Pack-years | 41 ± 19 | 40 ± 21 | 43 ± 22 | 45 ± 19 | < 0.01 |
Current smoker % | 33 | 30 | 15 | 14 | < 0.001 |
Medications % | |||||
Inhaled steroids | 15 | 25 | 56 | 52 | < 0.001 |
Oral corticosteroids | 0 | 0 | 0 | 0 | NS |
Physiology | |||||
FEV1% pred | 59 ± 13 | 52 ± 14 | 46 ± 14 | 44 ± 16 | < 0.01 |
FEV1/FVC % | 55 ± 9 | 51 ± 10 | 41 ± 9 | 43 ± 6 | < 0.01 |
Oxygen saturation % | 95.8 ± 2.9 | 96.2 ± 3.9 | 92.8 ± 3.4 | 91.4 ± 2.3 | < 0.001 |
Comorbidities (%) | |||||
Cardiovascular diseases | 15 | 20 | 17 | 13 | < 0.01 |
Osteoporosis | 18 | 20 | 35 | 42 | < 0.01 |
Diabetes | 9 | 10 | 5 | 6 | < 0.01 |
Longitudinal outcomes | |||||
COPD hospitalizations PPPY* | 0.4 | 0.8 | 1.6 | 3.4 | < 0.001 |
COPD exacerbations PPPY* | 1.2 | 2.6 | 3.4 | 3.8 | < 0.001 |
FEV1 decline mL·year−1 | 28 ± 26 | 32 ± 30 | 35 ± 33 | 36 ± 32 | < 0.01 |